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1. Introduction
SARS-CoV-2 has spread all over the 
world, over 192 countries with more than 
146 million confirmed cases and 3.1 mil-
lion deaths.[1] Even though there are 
numerous preclinical and clinical studies 
ongoing, unfortunately, there is cur-
rently no specific preventive or curative 
treatment for coronavirus disease 2019 
(COVID-19).[2,3] As discussed in various 
reports, nanotechnology and nanoma-
terials could provide solutions for the 
fight against COVID-19 in different ways, 
including: i) detection of viral particles; ii) 
protection of human exposure from viral 
particles via personal protection equip-
ment; iii) inactivation of viral particles by 
capture onto surfaces or different envi-
ronments; and iv) inactivation of viral 
particles through molecular surface inter-
actions with novel therapeutic drug mole-
cules (e.g., small molecules or antibodies) 
and vaccines.[4]
Nanotechnology can offer a number of options against coronavirus disease 
2019 (COVID-19) acting both extracellularly and intracellularly to the host 
cells. Here, the aim is to explore graphene oxide (GO), the most studied 2D 
nanomaterial in biomedical applications, as a nanoscale platform for interac-
tion with SARS-CoV-2. Molecular docking analyses of GO sheets on interac-
tion with three different structures: SARS-CoV-2 viral spike (open state – 6VYB 
or closed state – 6VXX), ACE2 (1R42), and the ACE2-bound spike complex 
(6M0J) are performed. GO shows high affinity for the surface of all three struc-
tures (6M0J, 6VYB and 6VXX). When binding affinities and involved bonding 
types are compared, GO interacts more strongly with the spike or ACE2, com-
pared to 6M0J. Infection experiments using infectious viral particles from four 
different clades as classified by Global Initiative on Sharing all Influenza Data 
(GISAID), are performed for validation purposes. Thin, biological-grade GO 
nanoscale (few hundred nanometers in lateral dimension) sheets are able to 
significantly reduce copies for three different viral clades. This data has dem-
onstrated that GO sheets have the capacity to interact with SARS-CoV-2 sur-
face components and disrupt infectivity even in the presence of any mutations 
on the viral spike. GO nanosheets are proposed to be further explored as a 
nanoscale platform for development of antiviral strategies against COVID-19.
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Since the early phases of the pandemic, computational 
models have been used to screen for drug molecules previ-
ously approved for other pathologies and disease conditions 
to be potentially repurposed against COVID-19.[5,6] Via these 
approaches, drugs such as remdesivir or toremifene have been 
reported to show high binding affinities against SARS-CoV-2 
proteins, including the spike protein or main protease.[7–10] Fol-
lowing these in silico and further pre-clinical evaluations, these 
drugs have been moved toward clinical trials, and remdesivir 
has recently been approved by the Food and Drug Administra-
tion for the treatment of COVID-19 requiring hospitalization.[11] 
During these computational simulations, different approaches 
can be used: Docking analysis is one of those, used to illumi-
nate the interaction processes of molecules that are spatially 
interacting to each other. The most critical information to be 
obtained from this process is to identify the ligand(s) that bind 
to protein epitopes most efficiently and determine the energy 
values of such binding interactions. In light of this information, 
one can anticipate to reveal new target proteins and the ways in 
which potential drug molecules could interact with them.[12,13] 
Molecular dynamics simulations (MDS) have mainly been used 
for conformation analysis of proteins. Conformational change 
processes take place in a short period of time (nanosecond to 
microsecond) and are impossible to follow experimentally. 
MDS enables us to visualize such experimentally challenging 
events. From such analysis, the aim has been to elucidate the 
role that amino acids play in ligand interactions and which 
amino acids provide structural stability to the protein.[14,15]
Several viral mechanisms can be shown as targets including 
the blockade of structural proteins responsible for entry into 
human cells or inhibition of important viral enzymes respon-
sible for genome replication or viral assembly.[2,3] Receptor 
binding domains (RBD) of the viral spike play a critical role in 
SARS-CoV-2 and ACE2 fusion, so this is a very relevant target 
complex for viral inhibition.[16] As described above, various ther-
apeutic strategies have been suggested to inhibit this interac-
tion. Among some of the clinically tested drugs, chloroquine/
hydroxychloroquine, arbidol, ribavirin, pensiclovir, favipiravir, 
nafamostat, nitazoxanide, and camostat mesylate have been 
shown to decrease virus–host cell binding or cellular internali-
zation or release.[17–22] Delineating the mechanisms of virus 
and cell interactions and viral life cycle, is not only important 
for the advancement of antiviral therapeutics, but also for the 
development of protective technologies from these viruses. For 
this reason, antiviral agents which show higher binding affinity 
and neutralization activity of viral particles have been included 
in the fabrication of personal protective equipment, including 
face masks. Copper, zinc, and polyethylenimine (PEI) are 
among such agents with antiviral activity that have been previ-
ously reported to increase inactivation efficiency in masks by 
improved viral entrapment without any toxicity to the user.[23–27]
Following the discovery of graphene, different classes of 
2D materials including transition-metal dichalcogenides 
(e.g., MoS2 and WSe2), transition metal carbides (MXenes, 
e.g., Ti3C2), hexagonal boron nitride (hBN), and graphitic 
carbon nitride (g-C3N4) have been developed.[28–31] Due to their 
unique physicochemical properties including optical and elec-
tronic properties, along with their diverse chemical composi-
tion and physicochemical properties including their good 
biocompatibility, these nanomaterials have attracted attention 
in various disciplines, including biomedical sciences.[32,33] 
Currently, applications such as anticancer therapeutics, mul-
timodal bioimaging, cancer theranostics, biosensing, tissue 
engineering, and antimicrobial coatings have been proposed 
and studied. Out of these 2D materials, graphene oxide (GO) is 
the most extensively explored in biomedicine. Various groups 
have shown how GO sheets interact with biological systems 
and fully characterize their toxicological, biodegradability, 
and tissue distribution profiles by detailed in vitro and in vivo 
experiments.[34–38]
The current study aims to offer a combined in silico and in 
vitro analysis to interrogate whether GO sheets can be consid-
ered as a nanomaterial platform able to interact effectively with 
specific SARS-CoV-2 surface proteins and receptors leading 
to an inhibitory action. Molecular docking experiments have 
been performed to understand how GO interacts with the viral 
spike, the ACE2 cell receptor, and the spike-ACE2 complex and 
identify the binding parameters that govern these interactions. 
Finally, a proof-of-concept study was performed in vitro (using 
Vero E6 cell cultures) to experimentally evaluate the effect of 
GO on the inhibition of wild-type SARS-CoV-2 infectivity. Four 
different infectious viral clades, as classified by the Global Ini-
tiative on Sharing All Influenza Data (GISAID) platform, have 
been used in order to better understand the inhibition of viral 
infection in the presence of mutations in viral proteins.
2. Results
It has been shown that 6M0J is the ACE2-bound form of SARS-
CoV-2 spike protein. According to the UniProt (The Universal 
Protein Resource) database (https://www.uniprot.org/uniprot/
P0DTC2), the 437–508 receptor-binding motif area of the 319–
541 amino acid receptor binding domain (RBD) of spike pro-
teins binds to the human-ACE2 protein (Figure 1A). The amino 
acids 30–41, 82–84, and 353–357 of ACE2 proteins are involved 
in this interaction (https://www.uniprot.org/uniprot/Q9BYF1). 
Examining the affinity of GO for the 6M0J could allow us to 
examine its effect on both the spike and ACE2 binding. The 
docking calculation results of GO and 6M0J are shown in 
Figure 2. Considering the docking results of GO with the 6M0J, 
GO showed affinity in 4 regions of the spike-ACE2 pair between 
values −9.1 kcal mol−1 to −8.4 kcal mol−1. However, three of these 
binding conditions (1st, 2nd, and 4th) are particularly important 
since they cover the entire SARS-CoV-2 infection process (spike, 
ACE2 and interface). When the highest binding affinity of GO-
Spike-ACE2 docking (−9.1  kcal mol−1) was examined in detail, 
GO showed strong affinity against amino acids of the spike-
RBD via 2 hydrophobic, 12 hydrogen, and 1 charge interaction 
with ASP427, a total of 15 bonds, and as well as 6 van der Waals 
forces which all explained the strong interaction with the ACE2 
(Figure 3). On closer examination, (Table S2, Supporting Infor-
mation) GO could act as a multiple H-donor and H-acceptor 
Prof. K. Kostarelos
Nanomedicine Lab  
National Graphene Institute and Faculty of Biology Medicine & Health
The University of Manchester




2101483 (3 of 13) © 2021 The Authors. Small published by Wiley-VCH GmbH
with strong H-bonds ranging from 1.74 Å to 2.93 Å. Moreover, 
electrostatic-pi–anion interaction of 427 ASP spike residue with 
GO is important for both increasing the binding strength and 
affecting the load density in the close chemical environment. In 
addition, GO formed van der Waals bonds with the following 
amino acid residues of ACE2: PRO321, MET383, ALA384, 
PHE55, ARG559, and ALA387. The 2nd and 4th positions of the 
GO:6M0J docking results are also shown in Figure S2, Table S3, 
and Figure S3, Table S4, respectively). Overall, it could be con-
cluded that GO strongly bound on the surface of 6M0J.
The 3-stranded glycoproteins 6VYB and 6VXX of SARS-
CoV-2 are those binding to ACE2 and correspond to open and 
closed states of the SARS-CoV-2 spike, respectively. The interac-
tion of GO with these proteins is shown in Figure 4A,B and the 
Figure 1. A) Schematic representation of viral spike and ACE2. SARS-CoV-2 binds to host cell receptor ACE2 through spike protein. Receptor binding 
domain (RBD) plays an important role during this interaction. Created with BioRender.com. B) Characterisation of GO material. I) Height AFM image 
(dimension: 5×5; scale bar: 1 µm) with insert of height cross-section profile along the indicated region in the height AFM image; II) corresponding 
lateral dimension distribution analysis (number of analyzed flakes: 356); III) SEM micrograph (scale bar: 1 µm); and IV) corresponding lateral dimen-
sion distribution (n = 116 analyzed flakes).
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affinity values are given in Table S4, Supporting Information. As 
seen in Figure 4A,B, GO has the potential to interact with each 
region of open and closed sate glycoproteins. The affinity values 
of these interactions ranged between −10.5, −9.4 and −9.0, 
−8.3 kcal mol−1, respectively (Table S5, Supporting Information). 
These high affinity values indicate that the bond strength should 
also be high. In addition, when the binding positions of GO in 
glycoproteins were examined, this indicated also an effective 
interaction, especially in relation to the RBD regions of the gly-
coproteins. GO acted as a strong hydrogen donor and acceptor 
(Tables S6 and S7; Figure S4–S6, Supporting Information) 
on interaction with both glycoproteins in the range of 2.214–
3.326 Å. In addition, GO has been shown to produce electro-
static interactions with both proteins (6VYB: A: LSY417; 6VXX: 
B: LYS462, C: ARG273, B: GLU465, C: ASP88) (Figures S4d 
and S5d, Supporting Information), while the chemical surface 
character of GO can change the charge load density.
During a SARS-CoV-2 infection event, blocking of the interac-
tion between the virus and host cells could be achieved by directly 
acting on the viral particles, the host cell receptors or the viral 
particles bound to the host receptor. To interrogate such pos-
sible interactions, we performed docking simulations between 
GO and ACE. Figure 4C shows the docking results of GO with 
1R42. When Figures  2 and  4C were evaluated comparatively, it 
was seen that the binding positions of GO and spike on the ACE2 
do not overlap. However, when binding affinity values are taken 
into account for these docking analyses, the difference between 
them was 0.8 kcal mol−1, indicating that GO binds more strongly 
to ACE2. This difference between binding strengths comes from 
the excess and diversity of the bonds formed between the GO and 
the ACE2 (Figures S3b and S6b, Supporting Information). When 
the bonding interactions were compared (Tables S4 and S8, 
Supporting Information), 7 hydrogen bonds and 2 hydrophobic 
interactions are obtained between GO and ACE2 binding (6M0J), 
while 12 hydrogen bonds, 2 hydrophobic, and 1 electrostatic inter-
action are calculated for ACE2. Therefore, it can be concluded 
that GO bound more strongly to the ACE2.
Based on the in silico investigations above, GO had been 
shown to have a strong affinity toward both the viral spike and 
the ACE2. In order to interrogate the possible implications of 
such interactions experimentally, we performed in vitro tests 
using infectious, wild-type SARS-CoV-2 virions. The biological-
grade GO material used in the studies has been developed 
for biomedical applications by our laboratories and are cur-
rently extensively explored in the context of various labs and 
projects. The characterization data of the specific batch of GO 
materials used in these studies are described in Figure 1B; and 
Figure S1, Supporting Information, in agreement with our pre-
vious reports.[39–43] The GO sheets used were thin (1–3 carbon 
layers) and of a few hundred nanometers in lateral dimension 
(100–400nm), with proven biocompatibility and purity.
Prior to testing antiviral activity, the possible cytotoxic impact 
of GO exposure to Vero E6 cells has been evaluated. As can be 
seen from Figure S7, Supporting Information, material did not 
show any significant toxicity up to 100 µg mL−1 in vitro in Vero 
E6 cells. Four different viral genotypes that have been previ-
ously deposited in GISAID platform, all corresponding to a dif-
ferent clade, were used for viral infection experiments. During 
in vitro experimentation, two different protocols were followed: 
a pre-infection and a post-infection protocol. In the pre-infec-
tion protocol, Vero E6 cells were first treated with the GO at 
different concentrations, and after 2 h viral particles at MOI of 
0.01 were added into the cell culture media. During the post-
infection protocol, cells were first incubated with the infectious 
virions and GO at different concentrations were added later 
onto the infected cell culture. Clade GR showed the highest and 
significant inhibition of infection in response to GO treatment 
(Figure 5A), reaching nearly a four-log reduction in viral copy 
number following the pre-infection protocol. On the other hand, 
S and GR showed significant inhibition only at the highest GO 
dose of 100 µg mL−1 (Figure 5B and 5C). The clade named as 
“other” was the least responsive to GO-mediated inhibition, 
although still a significant reduction of viral copy number was 
achieved at 100 µg mL−1 GO concentration (Figure 5D). Plaque-
forming assays were also performed in order to further validate 
the observed antiviral activity of GO against SARS-CoV-2 from 
Figure 2. The top nine docking results of GO and 6M0J. The binding 
regions of GO are numbered considering the binding affinity values. GO 
colored with green represents the highest binding affinity. Binding affini-
ties of these identified regions are given on the right.
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the GR clade. As can be seen in Figure 5E, treating the Vero E6 
cells with GO prior to viral infection with the GR clade resulted 
in an inhibition profile from which the median inhibitory con-
centration (IC50) was found to be around 30 µg mL−1. Whereas 
for the post-infection protocol, a higher IC50 value (45 µg mL−1) 
was obtained (Figure 5F). Arbidol which has been shown to be 
an effective drug in disrupting viral uptake in Vero E6 cells[18] 
has been also used as a “benchmark” therapeutic agent in our 
study. When the Vero E6 cells were pretreated with Arbidol 
at different dilutions, inhibition of viral infection could be 
observed both via qRT-PCR and plaque assays (Figure S8, Sup-
porting Infomration). This data supports that in both assays, 
which have been also extensively used in literature,[20,21,44] the 
GO antiviral activity could also be demonstrated. When the pre-
infection and post-infection protocols were compared, it could 
be seen that the inhibition level of viral infection was higher 
during the pre-infection protocol, as evident by both qRT-PCR 
and plaque assays. This agreed with the in silico analysis, since 
GO had been shown to have higher affinity toward the spike or 
ACE2 (a situation mimicked by pre-infection) compared to the 
spike-bound ACE2 (a situation mimicked by post-infection).
Finally, we went back to the in silico platform and have deline-
ated the effect of mutations found in the four different viral gen-
otypes used in the in vitro study. Molecular docking was applied 
to better explain the experimental results obtained in vitro. The 
mutation profile of all genotypes can be found in Table S9, Sup-
porting Information. GO is expected to mainly interact with the 
viral surface proteins and/or host cell surface receptors. For this 
reason, while considering the mutations on the viral genome, 
we mainly focused on the mutations of the spike protein. Both 
the GR and GH clades have a mutation at the spike structure, 
which is D614G. The GR clade showed more sensitivity against 
the GO compared to the GH clade, pointing out the importance 
of mutations found in the downstream viral proteins. However, 
all of these mutations are on the non-structural genes in the 
GH clade and their impact on overall viral infectivity has not yet 
been studied enough. The S clade, on the other hand, has a dif-
ferent spike mutation known as G1251V which is not within the 
receptor binding domain of the viral spike, and therefore is not 
expected to play an important role in the spike recognition. The 
clade represented as “other” didn’t show any mutation on the 
viral spike, representing a native form of the spike protein. We 
Figure 3. Detailed investigation of GO and 6M0J docking analysis. A) GO-6M0J docking result, binding affinity −9.1 kcal mol−1; B) 2D map of 6M0J 
amino acids bonding interactions with GO. Spike residues: TYR369, LYS378, CYS379, TYR380, GLY381, VAL382, SER383, ARG408, ALA411, PRO412, 
GLY413, GLN414, THR415, ASP427, ASP428, PHE429. ACE2 residues: PRO321, MET383, ALA384, ALA383, PHE555, ARG559; C) H-bonding: pink shows 
donors and green shows acceptors; D) Charge interaction with ASP427; E) Hydrophobicity (alkyl and pi-alkyl) interactions, LYS378.
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have performed molecular docking of GO on interaction with 
the mutated spike D614G, which is one of the mostly reported 
mutations causing increased infectivity of SARS-CoV-2 due 
to its effect on the receptor binding domain of the spike pro-
tein. To examine the effect of the D614G mutation on the spike 
protein, first, a structural prediction was made by replacing 
the 614th amino acid Asp in the B chain of 6VXX and 6VYB 
with Gly. After structural prediction, the structural compar-
ison – RMSD values between wild type and mutant structures 
were calculated to be 7.869 Å and 7.919 Å for 6VXXwt-6VXXmu 
and 6VYBwt-6VYBmu, respectively. The structural changes 
between the wild-type and the mutant viruses occurred in the 
RBD regions of the spike protein (Figure  6A). This structural 
change altered the donor–acceptor properties of the amino acid 
chain (Figure 6B) and consequently led to an increased binding 
strength and interaction between the GO sheets and the spike 
proteins (Figure 6C).
3. Discussion
Nanotechnology offers a number of possibilities for antiviral 
activity, both outside and inside the host cells. Several nano-
technology-based platforms have already been successful in 
preclinical studies to counter a variety of human viral patho-
gens such as HIV, human papilloma virus, herpes simplex, 
and respiratory viruses.[45–47] Moreover, nanoscale systems 
can potentially increase the effectiveness of drugs and other 
bioactive molecules by reducing the required effective dose, 
therefore dramatically improve the therapeutically effective 
drug toxicity thresholds. In the literature, there are numerous 
reports of antiviral drug delivery platforms suitable for different 
viral diseases and targets. Such platforms include liposomes, 
emulsions, de÷rimers, micelles, solid-lipid hydrogel based 
nanocarriers, polymeric nanoparticle, carbon-based and 2D 
materials.[48–50]
Figure 4. Docking of GO against open/closed state of Spike and IR42. A) GO with open state of spike (6VYB), 2nd affinity (highlighted in green) value 
corresponds to −10.4 kcal mol−1; B) GO with closed state of spike (6VXX), 4th and 7th affinity values correspond to −8.7 and −8.4 kcal mol−1, respec-
tively. C) The top nine docking results of GO and 1R42 are given on the right. The binding regions of GO are numbered considering the binding affinity 
values. GO colored with green represents the highest binding affinity.
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The field of nanotechnology has recently caught the atten-
tion of computational analysis in order to help scientists 
offer better understanding of nanomaterial interactions with 
biological systems.[4] Based on the data generated by such 
in silico analyses, nanotechnology-based therapeutic approaches 
could be improved.[51–53] Among 2D materials, GO is the most 
studied one using such computational models to depict interac-
tions with various biological moieties, mainly proteins.[54–61] For 
example, Baweja et al. reported that GO and reduced GO (rGO) 
were able to inhibit the α-helix to β-sheet transition of amyloid 
beta (Aβ) peptide, which has been implicated in the pathogen-
esis of Alzheimer’s disease.[55] In another study, Putri el al. 
studied via computational analysis the thermally responsive 
behavior of a polymer-GO complex in the design of a sensor 
with an “on/off” switch upon binding to a cancer cell marker 
at its lower critical solution temperature.[61] In silico approaches 
Figure 5. In vitro evaluation of GO mediated viral inhibition. Vero E6 cells were treated with GO (5, 10, 50, and 100 µg mL−1) and SARS-CoV-2 viral 
particles (MOI 0.1) according to a pre-infection or post-infection protocol. Four different viral genotypes were used which belong to A) GR, B) S, 
C) GH, and D) other clades according to GISAID. After 5 days, cell culture supernatants were used to quantify viral copy numbers by qRT-PCR. Vero 
E6 cells were treated with GO (5, 10, 50, and 100 µg mL−1) and SARS-CoV-2 viral particles (MOI 0.1) from clade GR according to E) pre-infection or 
F) post-infection protocol. % of inhibition was plotted following plaque assay. * p < 0.05, ***p < 0.001 compared to virus control.
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Figure 6. The effect of the D614G mutation on the interaction between GO and spike. A) Comparison of wild type and mutation structures of 6VXXwt-
6VXXmu and 6VYBwt-6VYBmu (colors – tawny-brown: wt; cyan: mutant) shows that the structural change occurred at the RBD. B) The D614G mutation 
effect on B wire of 6VXX and 6VYB are obtained. C) Molecular docking of GO against the mutated form of 6VXX and 6VYB was performed and binding 
affinities (ΔG kcal mol−1) of 6VYBmu and 6VXXmu were calculated.
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are becoming valuable tools to better understand the thera-
peutic potential of nanomaterial-drug conjugates, including 2D 
materials.
Considering the urgent need to offer as many options as pos-
sible in managing the SARS-CoV-2 pandemic, such computa-
tional methods are especially important to guide the rational 
design of new nanoscale systems on interaction with the critical 
SARS-CoV-2 viral components. In our study, GO was shown 
to have affinity towards the spike protein, ACE2 receptors and 
spike-ACE2 complex. However, when the binding affinities 
and types of bonds were compared, GO was found to interfere 
more strongly to the viral spike (6VYB or 6VYB) and the ACE2 
(1R42) before binding to the virus ligand, compared to 6M0J. 
Based on this in silico observation, when cells were exposed to 
GO prior to viral treatment in the context of a pre-infection pro-
tocol closer to a preventive clinical senario, pronounced viral 
inhibition was observed compared to a post-infection protocol 
in vitro. In combination, in silico and in vitro analyses in this 
study emphasized the importance of the correlation between 
computational and experimental methodologies in evaluating 
the antiviral activity of nanoscale platforms suspended in physi-
ologically relevant aqueous solutions.
2D nanomaterials, due to their extremely large surface area, 
can be superior carriers for antiviral drug delivery purposes 
compared to other materials with different structural confor-
mations and dimensions. 2D nanomaterials indeed have been 
explored in various preclinical studies for the delivery of cyto-
toxic agents, such as MTX, DOX or 5-FU (among others) to 
cancer cells for chemotherapeutic applications.[62–64] Although 
much attention has been placed on cancer therapy, there are 
studies suggesting that these materials are also promising can-
didates for anti-microbial therapies. Experimental studies have 
shown that the interaction between graphene-related 2D mate-
rials and bacteria, viruses and fungi could lead to strong anti-
bacterial and antiviral activities.[65] For example graphene oxide 
(GO) derivatives have been shown to compete with the cell sur-
face receptor heparan sulfate in binding herpes simplex virus 
type-1 (HSV-1).[66] Another study reported the broad-spectrum 
antiviral activity of GO against pseudorabies virus (PRV, a DNA 
virus) and porcine epidemic diarrhea virus (PEDV, an RNA 
virus). According to these reports, GO significantly suppressed 
the infection of PRV and PEDV at non-cytotoxic concentra-
tions.[67] Deokar et al. also showed the design and synthesis of 
sulfonated magnetic nanoparticles functionalized with reduced 
graphene oxide (SMRGO) to capture and photothermally 
destroy HSV-1.[68] In a more recent study by Donskyi et  al., a 
series of graphene derivatives with defined polyglycerol sulfate 
and fatty amine functionalities have been synthesized and their 
interactions with HSV-1 were investigated. When 2D sheets 
were functionalized with C6- and C9-alkyl chains, they showed 
efficient inhibition of HSV-1 without any significant toxicity in 
VeroE6 cells, suggesting that antiviral agents against HSV-1 can 
be obtained by controlled and stepwise functionalization of gra-
phene sheets.[69]
Recently, several groups started reporting the antiviral activi-
ties of different nanomaterials against the novel SARS-CoV-2 
virus. Nanoparticles containing silver, aluminum nitride or 
copper have been suggested to inhibit SARS-CoV-2 infec-
tivity.[70–73] In another approach, Zhang et  al. constructed 
cellular nanosponges which display cellular receptors of the 
virus on the surface, to demonstrate that these nanosponges 
were able to neutralize viral particles resulting in inhibition of 
infection.[74] In contrast, studies evaluating the antiviral activity 
of 2D materials are very limited. In one of two studies to do 
so, Raval et  al. reported a simple, initial computational anal-
ysis showing interaction between graphene and the receptor-
binding domain of spike complexed with its receptor ACE2. The 
molecular simulation data using pristine multi-layer graphene 
reported interactions with SARS-CoV-2 proteins, but no experi-
mental work was offered to validate the computational obser-
vations.[75] However, inhibition of viral infection can happen 
not only at the spike – ACE2 complex, but also at the spike or 
ACE2. As can be seen in our study, comparing docking analysis 
at different protein domains is crucial to better evaluate the 
inhibitory effect of nanomaterials. In the context of graphene 
or GO incorporated in personal protective equipment (PPE), De 
Maio et al. recently reported that GO could reduce SARS-CoV-2 
infectivity in vitro.[76] However, the GO concentration range 
selected is excessive and not realistic for the purposes of anti-
viral therapeutics. Furthermore, given that there are different 
viral clades spreading among patient populations, it was impor-
tant to evaluate the effectiveness of graphene or GO functional-
ized PPEs against multiple infectious viral genotypes.
In our present study, it is shown that GO can lead to reduced 
SARS-CoV-2 infectivity in 3 out of 4 infectious viral clades 
tested. Differences in viral inhibition among viral clades could 
be attributed to the mutations found in the viral genotypes. 
When GO was docked against one of the mutated regions, 
enhanced binding affinity was observed. For example, D614G 
mutation in the viral spike, which has also been reported to 
cause higher infectivity among human populations, was found 
to cause a structural change at 6VXX.[77–80] Based on this knowl-
edge and the experimental data obtained in vitro, when GO was 
computationally docked against one of these mutated spike 
regions, enhanced binding affinity was observed. We postulate 
that further interference of all viral genotype mutations that 
may be encountered in human populations can be achieved 
via appropriate engineering the GO material properties via sur-
face functionalization. In addition to the D614G mutation, it 
has been recently reported in GISAID platform that the other 
most common receptor binding mutations S477N (part of large 
Melbourne outbreak from clade GR and some Central Euro-
pean clade GH clusters), N439K (the long lasting UK outbreak 
with clade G and the European spillover), N501Y (the new UK 
variant VUI-202012/01 in clade GR and a recent clade GH out-
break in South Africa) and Y453F (the mink adaptation) as well 
as combinations of these mutations with deletions alter the 
surface of spike protein. These changes will certainly affect its 
affinity for host receptors, as well as the antiviral nanomate-
rials being developed. Therefore, our findings actually show the 
importance of considering different viral genotypes/mutations 
that will arise also in the future, in order to better understand 
the effect of nanomaterials tested against SARS-CoV-2. Overall, 
our observations suggest that GO can be considered a prom-
ising candidate to be used as an antiviral platform nanomaterial 
in the design of either PPE able to capture and retain viral par-
ticles[76] for disease prevention, or as an antiviral drug delivery 
system for therapeutic purposes.
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4. Experimental Section
Molecular Docking: The crystal structures of 6M0Ja, 1R42b, 6VXXc, 
and 6VYBc were obtained from the Research Collaboratory for Structural 
Bioinformatics Protein Data Bank (RSCB PDB).[81–83] These protein 
domains have been identified as: 6M0J: SARS-CoV-2 spike receptor-binding 
domain bound with ACE2, 1R42: native human Angiotensin Converting 
Enzyme (ACE2), 6VXX: SARS-CoV-2 spike glycoprotein (closed state) 
and 6VYB: spike ectodomain structure (open state). Prior preparation 
of protein domains (screening, removing waters, small molecules, and 
more), docking analysis, and image processing after analysis were all 
performed by Chimera version 1.14 and Discovery Studio 2020, which 
have been well-established in literature.[84,85] The free-standing GO surface 
(with functional groups on both sides of the layer) is optimized using 
modified AMBER force field and MD simulations. The split in the oxygen 
groups of GO is about: Epoxy oxygen 15% Hydroxy oxygen 10% Carboxy 
(edge groups) 5% (% calculated with respect to the total carbon atoms 
on the graphene layer). GO and protein models prepared in PDB format 
were converted to PDBQT format with the addition of Gasteiger partial 
charges via the AutoDock program version 4.2,[86] and grid box mapping 
parameters were also determined (Table S1, Supporting Information). In 
order to observe the affinity of GO against the whole protein structure, 
grid box parameters were adjusted to cover the whole protein. Finally, 
molecular docking analysis of GO and protein prepared in PDBQT format 
were performed using AutoDock-Vina,[87] which is a sensitive and high-
performance docking software. As a result of the calculations, nine results 
with the highest binding affinity were evaluated. For mutant analysis, the 
program Robetta was used for B chain structural prediction of 6VYB and 
6VXX proteins (https://robetta.bakerlab.org).
Material (Graphene Oxide) Synthesis and Characterisation: Synthesis of 
Biological-Grade GO: Biological-grade GO was synthesized from graphite 
powder (Sigma–Aldrich, UK) by the modified Hummers’ method as 
previously described.[88] Depyrogenation of all the glassware involved 
in the synthesis and the use of non-pyrogenic material was used to 
obtain endotoxin-free GO material suitable for biological applications.[38] 
Briefly, 18.4 mL of sulfuric acid was added to the mixture of the reaction 
containing 0.8 g of graphite and 0.4 g of sodium nitrate. Then, 2.4 g of 
potassium permanganate was added very slowly. After 30 min, 37.5 mL 
of water was transferred slowly and the reaction was kept at 98 °C for 
30 min. Afterward, 112.5 mL of water was added and also 12.5 mL of 30% 
hydrogen peroxide to stop the reaction. The consequent GO purification 
was performed by centrifugation steps until the pH of the supernatant 
was neutral. GO material was obtained after 5 min sonication and then 
purified by centrifugation.[39]
Atomic Force Microscopy: An Asylum MFP-3D atomic force microscope 
(Oxford instruments) operating in standard air-tapping mode and 
equipped with silicon probes (Ted Pella) with a resonance frequency 
of 300 kHZ and a nominal force of 40 N m−1 was used to characterize 
the surface. Samples were prepared by drop casting of 20  µL of GO 
suspension (100 µg mL−1) onto a freshly cleaved mica surface (Ted Pella) 
previously covered with 20  µL of poly-L-lysine 0.01% solution (Sigma-
Aldrich), subsequently washed with water, and then dried overnight at 
room temperature. Images were processed using Gwyddion software 
(http://gwyddion.net, version 2.56). Distribution analysis of 5 µm x 5 µm 
height AFM images to obtain the lateral dimensions was performed 
using ImageJ software (https://imagej.nih.gov).
Scanning Electron Microscopy: SEM images were recorded on a 
Magellan 400L field emission scanning electron microscope (Oxford 
instruments) at the ICN2 Electron Microscopy Unit, which was equipped 
with an Everhart-Thornley as secondary electrons detector and using 
an acceleration voltage of 20  kV and beam current of 0.1 nA. In each 
sample, 20  µL of GO material (100  µg mL−1) were deposited on an 
Ultrathin C on Lacey C grid; any excess of material was removed and 
dried overnight at room temperature. The lateral dimension distribution 
was obtained by measuring the flakes using ImageJ software.
Raman Spectroscopy: Raman spectra were acquired with a confocal 
Raman microscope (Witec) at room temperature coupled to 632  nm 
laser excitation and using a grating of 600 g nm−1. Single Raman spectra 
were collected on several spots after irradiation with a power of 1 mW 
for 10 s and using a 50x objective to focus on the sample. Samples were 
prepared by drop casting of 20 µL onto glass coverslip and then, dried 
overnight. The data were collected and analyzed with Origin software. 
The intensity ratio ID/IG was obtaining by taking the peak intensities 
without baseline correction.
Zeta Potential Measurements: Zeta potential (ζ) was measured by a 
Zeta-sizer Nano ZS (Malvern instruments) equipped with disposable 
capillary cells at the ICN2 Molecular Spectroscopy and Optical 
Microscopy Facility. Water dispersant settings for refractive index and 
viscosity, and automatic analysis were used for all GO measurements 
(20  µg mL−1). Each sample was measured three times at room 
temperature.
UV–Vis Spectroscopy: Absorbance was evaluated by using a Nanodrop 
2000c spectrophotometer (Thermo Scientific) at room temperature 
using a Hellma QS Quartz micro cuvette. GO samples were prepared in 
water in a concentration range of 2.5–20 µg mL−1.
X-Ray Photoemission Spectroscopy: XPS data was obtained using a 
Phoibos 150 (SPECS, GmbH) electron spectrometer equipped with a 
hemispherical analyzer, operating under ultrahigh-vacuum conditions, 
and with an Al Kα (hν  = 1486.74  eV) X-ray source, at the ICN2 
Photoemission Spectroscopy Facility. Charge effects on the samples were 
removed by taking the C1s line from adventitious carbon at 284.6  eV. 
Samples were prepared by deposition of 20 µg of GO material onto 5×5 
silicon wafers (Ted Pella) and dried overnight. In order to estimate the 
photoelectron peak intensities, CasaXPS software (http://www.casaxps.
com) was used.
Cell Culture: African green monkey kidney Vero E6 cell line was 
purchased from ATCC and maintained in DMEM media containing 
10% FBS and 1% antibiotics. Four local SARS-CoV-2 isolates (hCoV-19/
Turkey/HSGM-302/2020 (Clade GR), hCoV-19/Turkey/HSGM-439/2020 
(Clade other), hCoV-19/Turkey/HSGM-1049/2020 (Clade GH), and 
hCoV-19/Turkey/HSGM-1027/2020 (Clade S) with GISAID accession 
numbers of EPI_ISL_437313|2020-03-27, EPI_ISL_437307|2020-03-25, 
EPI_ISL_437309|2020-03-26 and EPI_ISL_437317|2020-03-27, respectively) 
was used in this study. Viruses were propagated in Vero E6 cells by using 
DMEM media containing 2% FBS and 1% antibiotics. All virus-related 
experiments were performed at Biosafety Level 3 laboratories.
Viral Infection: Vero E6 cells were seeded onto 96-well plates at 
confluency. Cells were either incubated with GO (5, 10, 50, 100 µg mL−1) 
or SARS-CoV-2 (MOI 0.1) in a pre-infection or post-infection protocol. 
In pre-infection protocol, cells were first treated with 100  µL media 
containing GO and after 2 h, viral particles were added onto the 
culture media. In a post-infection protocol, cells were first infected with 
SARS-CoV-2 (100  µL) and following 2 h of incubation, GO was added 
into the wells. After the final treatment, plates were incubated at 5% CO2 
at 37 °C. Plates were monitored for cytopathic activity for 5 days.
qRT-PCR Analysis: At the end of day 5, cell culture supernatants were 
collected. Total RNA was isolated via MPLC total nucleic acid isolation 
kit (Roche) using automated MagNA Pure LC Instrument (Roche). One-
step qRT-PCR was performed using the transcriptor one-step RT-PCR Kit 
(Roche) by using 5 µL of samples per each 20 µL reaction volume. In 
order to calculate viral copies per µL, a standard curve was constructed 
by using five different standards of known copy numbers according to 
the viral N gene.
Plaque Assay: Vero E6 cells were seeded onto 48-well plates at 
confluency. Cells were either incubated with GO (5, 10, 50, 100 µg mL−1) 
or SARS-CoV-2 (MOI 0.1) in a pre-infection or post-infection protocol. 
After 1h, carboxymethyl cellulose (CMC) overlay medium (300 µL) was 
added into each well. At the end of 4 days, plates were fixed with 10% 
formaldehyde and stained with crystal violet. Plaques were counted for 
each condition and plaque forming units were calculated. Based on 
pfu values, % of inhibition was calculated for each treatment group 
compared to the virus control group.
Statistical Analysis: All values were expressed as mean ±ST.D. 
Comparison between groups was performed by one-way ANOVA, 
followed by a Tukey’s post hoc multiple comparisons by the statistics 
program GraphPad. At least three independent replicated were analyzed.
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